Session » (0040–0064) Innate Immunity Poster

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0044

Aberrant Mevalonate Metabolite Farnesyl Pyrophosphate-Induced Neutrophil Hyperactivation in Behçet’s Disease Pathogenesis

9:00AM-11:00AM: Abstract Number: 0050

Anti-Citrullinated Histone Antibody CIT-013, a Dual Action Therapeutic for Neutrophil Extracellular Trap Associated Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 0043

Assessing the Ability of Human Dental Pulp Stem Cells to Modulate the Macrophages Phenotype

9:00AM-11:00AM: Abstract Number: 0051

CD14+CD64+ Classical Monocytes Are the Main Producers of IL-23 at the Enthesis

9:00AM-11:00AM: Abstract Number: 0046

Circulating Monocytes in RA, SSc, and SLE Have Radically Altered and Unique Transcriptional & Epigenetic Profiles

9:00AM-11:00AM: Abstract Number: 0064

Correlation of Anti-DFS70 Autoantibodies by ELISA with HEp-2 Cells DFS Pattern by IFA

9:00AM-11:00AM: Abstract Number: 0062

Differential Metabolic Profiles, Activation and Circadian Dynamics in Rheumatoid Arthritis and Psoriatic Arthritis Circulatory Monocytes

9:00AM-11:00AM: Abstract Number: 0045

Discovery and Characterization of a Selective, Orally Bioavailable PAD4 Inhibitor to Target NETs Driven Autoimmune and Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 0061

Discovery of a RIPK2 Scaffolding Inhibitor for the Treatment of Joint Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 0042

Effect of the Inflammatory Microenvironment Induced by Monocytes on Fibroblasts and Modulatory Action of Human Dental Pulp Stem Cells

9:00AM-11:00AM: Abstract Number: 0055

Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses

9:00AM-11:00AM: Abstract Number: 0059

GM-CSF by Natural Killer Cells Drives Inflammatory Arthritis in HIV-Infected Humanized Mice

9:00AM-11:00AM: Abstract Number: 0057

GM-CSF receptor/SYK/JNK/FOXO1/CD11c Signaling Enhances Cell Migration to Promote Atherosclerosis

9:00AM-11:00AM: Abstract Number: 0047

Identification of Specific Monocyte Epigenetic Signatures in Sarcoidosis and Tuberculosis

9:00AM-11:00AM: Abstract Number: 0041

Interactions Between Synovial Fibroblasts and Macrophages: Implications for Tissue Remodeling in Chronic Inflammatory Diseases and Macrophage Differentiation in Response to the Immune Microenvironment

9:00AM-11:00AM: Abstract Number: 0063

Investigating Macrophage Repopulation in the Synovium

9:00AM-11:00AM: Abstract Number: 0058

Macrophage Extracellular Traps Induced by Monosodium Urate or Calcium Pyrophosphate Crystals Form Independently of NLRP3 Inflammasome Activation

9:00AM-11:00AM: Abstract Number: 0048

Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares

9:00AM-11:00AM: Abstract Number: 0053

Nintedanib Downregulates the Profibrotic M2 Phenotype of Macrophages Obtained from Systemic Sclerosis Patients Affected by Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 0040

Non-canonical NF-κB Signalling Is Required for Extrathymic AIRE Expression and Immunoregulatory Molecules in Cells of the Dendritic Lineage

9:00AM-11:00AM: Abstract Number: 0052

Possible Involvement of TLR4 in the Pathogenesis of Primary Sjögren’s Syndrome Through Induction of the Expression of BAFF Receptor, BR3 in Peripheral Monocytes

9:00AM-11:00AM: Abstract Number: 0054

RA Monocytes and Monocyte-Derived Macrophages Display Heightened Inflammatory Responses, Reduced Endocytic Capacity and Distinct TET Expression Compared to PsA Monocytes

9:00AM-11:00AM: Abstract Number: 0060

Serpin B1 Modulation of Immune Complex-Mediated Neutrophil Activation and NET-formation Requires Its Chymotrypsin-like Inhibitory Activity

9:00AM-11:00AM: Abstract Number: 0049

Soluble Uric Acid Is an Endogenous Inhibitor of CD38

9:00AM-11:00AM: Abstract Number: 0056

The Activation of cGAS-STING Pathway in Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].